Slide 1: Twelve-month financial report (1 Dec 2020 – 30 November 2021)
Global virtual care provider within the telerehabilitation sector Twelve-month financial report (1 Dec 2020 – 30 November 2021) Webcast presentation | January 26th 10:00 CET
Slide 2: Forward-looking statement
Forward-looking statement This presentation contains certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as “beli
Slide 3: Agenda
Agenda Introduction Q4 in short Business update Financial results Strategy and Outlook Q&A Henrik Molin CEO & co-founder Charlotte Goodwin CFO 3
Slide 4: Introduction
Introduction sb Physitrack:
Slide 5: Who we are
Who we are Physitrack is a global remote physical therapy SaaS provider for remote patient engagement B2B virtual care SaaS High Growth - Multibillion addressable Pure play SaaS (90%) High Profitability market with strong SaaS enabled virtual care philosophy digitalisation drivers (10%) Pictures: Hi
Slide 6: Timeline of growth and expansion
Timeline of growth and expansion Acquisition of Global Covid-19 pandemic Physitrack Physiotools to accelerates the digital Acquisition of Acquisition of PT launches SaaS expand in Nordics transformation of the Fysiotest to Courses enhances platform and enhance SaaS healthcare industry enhance virtua
Slide 7: Q4 in short
sb Physitrack:
Slide 8: Outstanding growth of SaaS and Virtual care business
Outstanding growth of SaaS and PT Courses acquisition Operational alignment of Virtual care business Physiotools and Physitrack 153% 12 month revenue growth - Physiotools and Physitrack - Strengthens our presence operational alignment in USA across several teams 12 month proforma 36% revenue growth
Slide 9: Business updates
Business updates sb Physitrack:
Slide 10: Outstanding growth of underlying SaaS business in-line with strategic objectives
Outstanding growth of underlying SaaS business in-line with strategic objectives 16% growth in Physitrack users 45,000 27% growth in Physiotools licenses 40,000 16% 35,000 30,000 Continued growth of Custom App 25,000 • Physitrack’s Custom app product is a white label solution which provides 20,000 e
Slide 11: PT Courses
PT Courses On 26 January 2022 Physitrack PLC announced the acquisition of PT Courses, a company registered in the US. PT Courses, is a provider of continued education courses for physiotherapists and occupational therapy professionals in the US. 11
Slide 12: PT Courses
PT Courses Acquisition allows enhancements of SaaS product to include continued education The acquisition is financed by upfront cash consideration of $1.8 million, with no earn-out. For the year ended 31 December 2021, PT Courses expected to achieve revenues of USD 0.6m and Adjusted EBITDA of USD 0
Slide 13: Financial Results
Financial Results sb Physitrack:
Slide 14: Q4 Financial Highlights
Q4 Financial Highlights 12 month revenue Q4 revenue 153% 165% €7.7m (2020: €3.1m) €2.4m (2020: €1.0m) 12 month proforma 36% Q4 proforma 47% revenue growth revenue growth 12 month adjusted EBITDA 12 month adjusted EBITDA margin 58% €2.6m (2020: €1.6m) 33% (2020: 53%) 20pp 14
Slide 15: Strong revenue growth
Strong revenue growth Beating medium term growth targets 9,000,000 3,000,000 8,000,000 7,000,000 36% 2,500,000 47% 6,000,000 2,000,000 5,000,000 153% 1,500,000 165% Euro Euro 4,000,000 3,000,000 1,000,000 2,000,000 500,000 1,000,000 - - 12 MONTHS 2019/20 12 MONTHS 2019/20 12 MONTHS 2020/21 Q1 Q2 Q3
Slide 16: EBITDA
EBITDA Stable growth excluding non-recurring costs 3,000,000 3.0 2,500,000 2.5 58% 0.8 2,000,000 2.0 €’million €1.6M €2.6M 1,500,000 1.5 €’million 0.4 0.7 €1.6M ADJUSTED 1,000,000 EBITDA 1.0 0.6 ADJUSTED Margin EBITDA 33% 0.6 Margin 53% 500,000 €1.0M 0.5 0.5 0.5 0.2 - - 12 MONTHS 12 MONTHS Non compa
Slide 17: Cashflow
CASHFLOW 20.0 Significant cash raised from IPO to fund further acquisitions and development 18.0 16.0 ( 2.4 ) (0.3) (0.4) 0.1 14.0 12.0 €’million 10.0 17.5 8.0 14.3 6.0 4.0 2.0 (0.5) (0.1) 2.6 (1.6) - (0.5) 1 Dec 2020 Adjusted EBITDA Working capital Interest expense Purchase of Issue of shares Purch
Slide 18: Balance Sheet
Balance Sheet Net assets position strengthened from IPO and goodwill recognised on acquisitions 30 November 2021 30 November 2020 Euros '000 Goodwill, intangibles and PPE 16,820 7,711 Cash and cash equivalents 14,327 1,254 Investments 79 - Borrowings (1) (1,737) Trade and other receivables 1,634 543
Slide 19: Strategy and outlook
Strategy and outloo sb Physitrack:
Slide 20: Executing a well-defined growth plan combining organic and inorganic initiatives
Executing a well-defined growth plan combining organic and inorganic initiatives Planning to build a global powerhouse in the remote physical care space through well-defined, tangible organic and inorganic growth objectives 3 M&A initiative 2 Continue strong M&A traction following the successful acq
Slide 21: Physitrack's Virtual Care Business – Introducing Holistic SaaS Product in 2022
Physitrack’s Virtual Care Business – Introducing Holistic SaaS Product in 2022 Financial Results 21
Slide 22: Physitrack's Virtual Care Business – Introducing Holistic SaaS Product in 2022
Physitrack’s Virtual Care Business – Introducing Holistic SaaS Product in 2022 Financial Results 22
Slide 23: Physitrack's Virtual Care Business – Introducing Holistic SaaS Product in 2022
Physitrack’s Virtual Care Business – Introducing Holistic SaaS Product in 2022 Financial Results 23
Slide 24: Financial goals – What we aim for
Financial goals – What we aim for Top-line growth Profit margins Value creation/distribution Physitrack aims to achieve annual Physitrack targets an EBITDA margin organic sales growth exceeding 30% in of 40-45% in the medium term, with Physitrack aims to reinvest profits the medium term, further pot
Slide 25: sb Physitrack:
sb Physitrack: